Recent Updates

Modified on: 
Feb 11, 2019

Decisions about blood safety need to take numerous factors into account, such as risks, benefits, costs, ethical issues, and stakeholder perspectives.

ABO has developed a unique framework to help blood service operators streamline the process and make responsible decisions that lead to the greatest good. Whether the blood safety decision to be made is small or large in scale, this framework can help to organize the process and to assure the quality of the information used to make the decision. 

Transfusion
Modified on: 
Feb 11, 2019

The International Collaboration for Transfusion Medicine Guidelines (ICTMG) was established in 2011 and includes international transfusion experts from around the world. 

Transfusion
Modified on: 
Feb 11, 2019
Canadian Blood Services delivers KnowledgeInfusion activities to disseminate research findings that are aligned with the goals of our organization in order to accelerate their uptake by the transfusion community. KnowledgeInfusion activities include Lunch&Learn webinars that are recorded and shared below. 
 

Extending platelet shelf life from 5 to 7 days

Transfusion
Modified on: 
Feb 8, 2019

Abnormal bleeding may result from defects in platelets, coagulation factors and/or blood vessels. Screening tests for coagulation factor abnormalities include the activated Partial Thromboplastin Time (aPTT) and Prothrombin Time (PT) / International Normalized Ratio (INR). Thrombocytopenia is the most common platelet defect. Qualitative platelet defects may also occur and, in some cases, may be associated with thrombocytopenia. In patients with platelet defects, bleeding time and/or closure times using the platelet function analyzer (PFA-100/200TM) may be prolonged. Vascular defects may be accompanied by joint hyperflexibility or skin laxity. Effective treatment of hemostatic disorders requires accurate diagnosis and special coagulation testing that may include coagulation factor assays, inhibitor assays, and platelet function tests. An algorithmic approach to diagnosis is beyond the scope of this review.

Transfusion
Modified on: 
Feb 7, 2019

Apheresis involves the removal of whole blood from an individual and its separation into components. A specified component is retained and the remainder is returned to the individual. Therapeutic apheresis is used to treat patients with a variety of disorders and has become a relatively common treatment modality. The rationale and techniques for therapeutic apheresis, as well as the care of the apheresis patient, will be discussed in this chapter.

Transfusion
Modified on: 
Feb 7, 2019

This chapter focuses on preoperative autologous donation (PAD). There are other types of autologous blood use (e.g. acute normovolemic hemodilution and intraoperative and postoperative blood salvage) which are not discussed in this chapter.

PAD refers to the donation of blood by a patient for his/her own future use; generally this is for a scheduled elective surgery. The top three procedures associated with a request for a PAD are total hip replacement, total knee replacement and hysterectomy.

In most cases, allogeneic blood transfusions are a safe and available option. Autologous and directed donations should be confined to circumstances of rare blood types or plasma protein deficiencies in which  allogeneic units may not meet patient needs. Rare blood types represent only a small number of autologous units collected each year. See Chapter 13 of this Guide for more information on directed donations.

Transfusion
Modified on: 
Feb 7, 2019

While the practice of transfusion of blood products to neonatal and pediatric recipients has much in common with the transfusion of blood products to adults, there are several important differences and special circumstances. This chapter highlights the most common considerations that are unique to this group of patients.

Transfusion
Modified on: 
Feb 7, 2019

Platelets are the smallest of the blood cells, with a diameter of two to three microns and no nucleus. Their main function is to mediate primary hemostasis, though they are involved in a number of other processes including primary immunity, tumour progression and inflammation. 

Transfusion
Modified on: 
Feb 7, 2019

The approach to transfusion in emergent situations varies dramatically depending on the clinical scenario. The primary guiding determinant is the clinician’s assessment of the rapidity of bleeding, the severity of hemorrhage or amount of blood lost, and the clinical stability of the patient. Using the severely injured trauma patient as a case study, this chapter will discuss the principles of massive hemorrhage and resuscitation, with the inclusion of special situations such as obstetrical hemorrhage, where data are available.

Transfusion

Pages